Silence Therapeutics Plc (SLN)

$23.35

+0.35

(+1.52%)

Market is closed - opens 7 PM, 21 May 2024

Insights on Silence Therapeutics Plc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 11.37M → 2.09M (in $), with an average decrease of 38.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.25M → -14.41M (in $), with an average decrease of 74.7% per quarter

Performance

  • $23.19
    $23.84
    $23.35
    downward going graph

    0.69%

    Downside

    Day's Volatility :2.73%

    Upside

    2.06%

    downward going graph
  • $4.84
    $27.72
    $23.35
    downward going graph

    79.27%

    Downside

    52 Weeks Volatility :82.54%

    Upside

    15.76%

    downward going graph

Returns

PeriodSilence Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
-5.97%
0.8%
0.0%
6 Months
132.09%
13.4%
0.0%
1 Year
283.33%
11.4%
0.0%
3 Years
-4.41%
17.7%
-19.9%

Highlights

Market Capitalization
1.1B
Book Value
$0.43
Earnings Per Share (EPS)
-1.47
Wall Street Target Price
57.66
Profit Margin
-170.51%
Operating Margin TTM
-633.59%
Return On Assets TTM
-30.8%
Return On Equity TTM
-221.19%
Revenue TTM
25.4M
Revenue Per Share TTM
0.68
Quarterly Revenue Growth YOY
-56.00000000000001%
Gross Profit TTM
6.6M
EBITDA
-49.3M
Diluted Eps TTM
-1.47
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    100%Buy
    0
    0%Hold
    0
    0%Sell
Based on 3 Wall street analysts offering stock ratings for Silence Therapeutics Plc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 146.94%

Current $23.35
Target $57.66

Technicals Summary

Sell

Neutral

Buy

Silence Therapeutics Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Silence Therapeutics Plc
Silence Therapeutics Plc
2.22%
132.09%
283.33%
-4.41%
-4.41%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Silence Therapeutics Plc
Silence Therapeutics Plc
NA
NA
NA
0.0
-2.21
-0.31
NA
0.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Silence Therapeutics Plc
Silence Therapeutics Plc
Buy
$1.1B
-4.41%
NA
-170.51%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • Lombard Odier Asset Management USA Corp

    10.03%
  • Lombard Odier Asset Management (EU) Ltd

    9.34%
  • Artal Group S A

    7.76%
  • TCG Crossover Management, LLC

    5.44%
  • Deep Track Capital, LP

    5.05%
  • Aquilo Capital Management, LLC

    2.70%

Corporate Announcements

  • Silence Therapeutics Plc Earnings

    Silence Therapeutics Plc’s price-to-earnings ratio stands at None

    Read More

Company Information

silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com

Organization
Silence Therapeutics Plc
Employees
109
CEO
Mr. Craig A. Tooman M.B.A.
Industry
Health Technology

FAQs